$Dapagliflozin significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial 1$

Dapagliflozin significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial

September 9, 2022

6:34 am

News Update

admin

Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaningful benefits of dapagliflozin in patients with heart failure regardless of ejection fraction Heart failure is a chronic, progressive disease impacting nearly 64

POST TAGS:

AstraZeneca BioPharmaceuticals Dapagliflozin Dr. Anil Kukreja Dr. VK Chopra Health Max Super Speciality Hospital

Dapagliflozin significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial

POST TAGS:

FIND US

ADDRESS

FOLLOW US ON SOCIAL MEDIA

Dapagliflozin significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial

POST TAGS:

FIND US

ADDRESS

FOLLOW US ON SOCIAL MEDIA

Every major healthcare update,delivered to your inbox

Every major healthcare update,
delivered to your inbox